“…To start, differences in GM between SAD-patients and healthy controls have been reported for a number of subcortical, frontal, temporal and parietal regions [ 49 , 50 , 59 , 60 , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] ] – see Table 1 for an overview of MRI-studies on GM in SAD. Furthermore, changes in brain structure were shown to be associated with clinical characteristics [ 49 , 50 , [54] , [55] , [56] , [57] , [58] , 60 , 61 ], while treatment-related changes in brain structure in SAD patients have also been described [ [62] , [63] , [64] ]. Although it should be noted that the findings reported in these studies are heterogeneous (see Table 1 and review by Brühl and colleagues [ 65 ]), and have small effect sizes [ 60 ], a machine learning study was able to discriminate SAD-patients from healthy controls based on GM changes over the whole brain [ 66 ].…”